Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms.

Bruce is chairman and was founding CEO of Kymera Therapeutics (NASDAQ: KYMR) and Nimbus Therapeutics. He also serves as chairman of Hotspot Therapeutics, Matchpoint Therapeutics, and Vigil Neuroscience (NASDAQ: VIGL), and is a board member of Lifordi Immunotherapeutics and Sionna Therapeutics (NASDAQ: SION), as well as several seed stage companies. He previously served on the boards of prior Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics (acquired by Bial), Nimbus Lakshmi (acquired by Takeda), Padlock Therapeutics (acquired by BMS), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), and a number of other ventures.

Bruce serves or has served as an advisor in various capacities to Takeda, UCB, the Gates Foundation, and the Penn State Research Foundation. He recently joined the board of the Appalachian Mountain Club (AMC) to support outdoor recreation and conservation. He also volunteers as a coach with New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Bruce enjoys running, skiing, hiking, and fishing. He lives in Wellesley, MA and has three wonderful kids.